Allegra Allergy

Quick links

Choose a section

Quick links to important sections

Advertisements

Allegra Allergy

Advertisements
Advertisements

Treatment option: Allergy, Hives, Rhinitis, Hay Fever

Advertisements

Overview of Allegra Allergy

Quick Facts About Allegra Allergy

Property Description
Active Ingredient Fexofenadine Hydrochloride
Form Oral tablets or capsules
Pharmacological Class Second-Generation H₁ Antihistamine
Common Use Symptomatic relief of allergies (e.g., hay fever)
Origin Synthetic (man-made compound)

Allegra Allergy: The Basics (What It Is and What It Contains)

Allegra Allergy is a clinically recognized non-prescription (OTC) medication used for the relief of allergy symptoms, belonging to the class of drugs known as antihistamines. Its primary active ingredient is fexofenadine hydrochloride, which acts as the core therapeutic substance. Allegra Allergy is commonly available in various oral tablet forms, making it a convenient option for quick, systemic relief.

The medication's composition contains only fexofenadine, an API supported by pharmacological research. This means the medicine works directly on the allergy response by blocking a specific chemical in your body.


Is Allegra Allergy a Natural or Synthetic Drug? (Pharmacological Class and Origin)

The active substance, fexofenadine, is a purely synthetic compound, which ensures consistent purity and potency in every dose. Allegra Allergy is classified as a second-generation H₁ antihistamine. This classification is a key element of its brand positioning.

This designation is clinically significant because the compound has been engineered for non-sedating properties, distinguishing it from many older allergy drugs. This feature is widely recognized by medical professionals, making it a preferred choice for individuals who need to maintain alertness throughout the day. This makes the drug a reliable choice for managing hay fever without the concern of excessive drowsiness.


What Is the General Therapeutic Purpose of Allegra Allergy? (Why It's Used)

The general therapeutic purpose of Allegra Allergy is to manage the temporary discomfort caused by exposure to allergens. A typical use scenario involves relieving symptoms like sneezing and itching that occur shortly after exposure to seasonal allergens, such as pollen. The drug is used to provide effective relief from the symptoms associated with seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). Its function is to intercept the body's allergic response, helping individuals restore comfort and improve daily functioning.

Regulatory References

  1. Fexofenadine - StatPearls - NCBI Bookshelf
  2. FEXOFENADINE HYDROCHLORIDE tablet, film coated - DailyMed
Advertisements

What side effects are possible with Allegra Allergy?

Possible Side Effects and Safety Information

The safety profile for fexofenadine hydrochloride (Allegra Allergy) is established through clinical trials and post-marketing surveillance, with adverse reactions categorized by frequency and the body systems affected.

Frequency-Classified Adverse Reactions

Official regulatory documents classify adverse effects into specific frequency categories, which vary slightly between US and European agencies. Reactions commonly listed in adult clinical trial data include Headache, Dizziness, Nausea, and Fatigue.

System-Organ Class (SOC) Examples of Documented Reactions
Nervous System Disorders Headache, Dizziness, Drowsiness, Insomnia
Gastrointestinal Disorders Nausea, Dry mouth, Stomach discomfort, Diarrhea
Cardiac Disorders Palpitations, Tachycardia (Frequency Not Known)

Serious Adverse Reactions and Safety Considerations

Rare but clinically significant adverse events are primarily reported through post-marketing surveillance and are classified as having a Frequency Not Known. These include severe Hypersensitivity Reactions such as Angioedema (swelling), Dyspnea (shortness of breath), and Systemic Anaphylaxis.

Population-Specific Safety Notes are defined in regulatory labeling. Older adults (age ge 65 years) and patients with renal impairment may require caution because drug clearance is reduced, which can lead to higher systemic exposure to the active ingredient. Additionally, the label notes that pediatric patients (ages 6–11) may experience different common reactions, such as Cough and Upper Respiratory Tract Infection.

Safety Restrictions define specific limitations, including a contraindication for individuals with a known hypersensitivity to any component of the medication. Caution is also advised regarding concomitant use with antacids containing aluminum and magnesium hydroxide, as this interaction is documented to reduce fexofenadine's absorption.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation addresses the manifestations and required immediate actions in cases of Fexofenadine Hydrochloride (Allegra Allergy) overdose. The primary warning states that taking more than directed can cause serious health problems, requiring immediate medical attention.


Documented Overdose Manifestations and Action

Clinical data recorded in regulatory sources indicate that an overdose may present with specific symptoms. This information is critical for determining the mandated emergency response.

Overdose Entity Official Regulatory Statement
Documented Symptoms Dizziness, Drowsiness (Somnolence), and Dry Mouth
Immediate Action Required Get medical help or contact a Poison Control Center right away
Management Strategy Symptomatic and supportive treatment is recommended; procedures to remove unabsorbed drug should be considered.
Antidote Status No specific antidote is known

Special Population Considerations

Official labeling contains specific notes for certain populations regarding the use of the medication, which are particularly relevant in the context of overdose, including consumers with kidney disease and adults 65 years of age and older. Both groups are officially instructed to consult a doctor before use, as renal impairment can affect the drug's elimination, impacting the overall overdose scenario.

Advertisements

Therapeutic Uses of Allegra Allergy

What Allegra Allergy Treats: Main Uses and Benefits

Allegra Allergy is used across therapeutic domains involving heightened allergic responses. It is commonly applied in settings where symptoms create noticeable physiological strain, offering supportive assistance that contributes to easing overall discomfort.

The medication is relevant for managing two core condition categories marked by disruptive symptom manifestations: Seasonal Allergic Rhinitis (hay fever) and Chronic Idiopathic Urticaria (hives).

The medication is used to help with symptomatic relief during periods of seasonal allergic rhinitis, addressing symptom clusters that may become intense, including repetitive sneezing, runny nose, and itching of the nose or throat. It is also applied in conditions characterized by chronic skin manifestations. This supportive relief assists with maintaining functional stability and alertness.


Quick Fact: Symptomatic Relief Domains

Condition Category Symptom Management Area Patient Benefit Context
Seasonal Allergic Rhinitis Nasal and Ocular Symptoms Supports coping during high allergen exposure
Chronic Idiopathic Urticaria Persistent Skin Itching and Welts Assists with stability during chronic episodes

Regulatory References

  1. FDA-Approved Labeling via DailyMed
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Allegra Allergy (Fexofenadine HCl)

Regulatory documents establish specific criteria for the eligible use of Allegra Allergy, focusing on age, physical state, and pre-existing conditions.


Eligibility and Restrictions

Population Group Eligibility Status (Regulatory Wording)
Absolute Contraindication Contraindicated in patients with known hypersensitivity to fexofenadine or any excipients.
Adults and Adolescents Generally approved for individuals 12 years and older (tablets).
Children Approved for children 6 years and older (tablets) and as young as 6 months (oral suspension) for specific indications.
Infants (< 6 months) Safety and efficacy have not been established.
Renal Impairment Requires a dose adjustment due to slower drug clearance.
Pregnancy Classified as Category C; use only if the potential benefit justifies the potential risk.
Lactation Not recommended or should be used with caution.
Phenylketonuria (PKU) Restricted from using the Orally Disintegrating Tablet (ODT) formulation.

Use is generally permitted for geriatric subjects (65 years old), but may require dose consideration if reduced kidney function is present. Patients with a history of heart disease are advised to use the medication with caution due to general antihistamine class warnings.

Advertisements

What should I know about interactions with other medicines?

The official regulatory interaction profile for Allegra Allergy (fexofenadine hydrochloride) is defined primarily by interactions that alter its systemic exposure through transport systems rather than liver metabolism. Fexofenadine undergoes negligible hepatic metabolism, meaning it does not have documented clinically significant interactions via the cytochrome P450 (CYP) enzyme system.

Documented Exposure Modification

Several medicinal products are officially documented to modify fexofenadine plasma concentrations. Co-administration of the antifungal Ketoconazole and the antibiotic Erythromycin significantly increases fexofenadine exposure (AUC and Cmax) through documented effects on the P-glycoprotein (P-gp) transport system. In contrast, Antacids containing aluminum and magnesium hydroxide cause a significant reduction in fexofenadine bioavailability due to physical interference in the gastrointestinal tract. This interference necessitates a mandatory 2-hour separation between the administration of fexofenadine and these antacids.

Official Restrictions and Constraints

The product label includes specific constraints related to ingestion and procedures. Consumption of certain fruit juices (including grapefruit, orange, and apple) is restricted because they are documented to reduce the drug's systemic exposure; the medicine must be taken with water. A pharmacodynamic restriction requires that fexofenadine administration be stopped several days before skin testing using allergen extracts, as the drug suppresses the cutaneous histamine response. Furthermore, for patients with renal impairment, official documents note a documented reduction in fexofenadine clearance, leading to increased overall systemic exposure.

Advertisements

Mechanism of Action

Selective H1 Receptor Antagonism

Fexofenadine acts as a selective H1 receptor antagonist. This mechanistic domain involves the molecule binding directly to H1 receptors found on the surface of various cells, including those in the respiratory tract and skin. This action competitively blocks the binding of endogenous histamine, which is a key physiological mediator released by mast cells during certain immune responses. The molecular consequence is the interruption of the signaling cascade normally initiated by histamine-receptor interaction, thereby affecting downstream cellular activity and process activation.


Modulation of Inflammatory Mediator Activity

This mechanism extends beyond primary receptor blockade to include modulating key cellular pathways associated with certain immune cell responses. Fexofenadine engages mechanisms that influence feedback regulation within these pathways, specifically resulting in the inhibition of select inflammatory mediator release from mast cells and basophils, which is distinct from its H1 receptor activity. This influence on mediator release pathways modifies the net activity of key cellular processes and contributes to the overall pathway activity profile.

Advertisements

Dosage and Administration Information

How Allegra Allergy is Used: Official Administration Guidelines

The usage of Allegra Allergy (fexofenadine hydrochloride) is governed by specific oral administration principles, defining the appropriate dosage, timing, and conditions of intake.

Standard Dosage and Frequency

Fexofenadine is administered by the oral route in several available formulations, including tablets, orally disintegrating tablets (ODT), and suspension.

For adults and adolescents 12 years of age and older, the standard dose for approved indications is either 180 mg taken once daily (QD) or 60 mg taken twice daily (BID), typically separated by 12 hours. The maximum daily dosage is 180 mg. For pediatric patients between 6 and 11 years of age, the standard regimen is 30 mg twice daily.


Administration Conditions and Adjustments

Adherence to the proper administration context is required. The tablet form of the medicine must be taken with water and should not be administered alongside fruit juices, such as grapefruit, apple, or orange juice. Additionally, concomitant use with aluminum or magnesium antacids should be avoided, as this may interfere with proper absorption.

Specific dosage adjustments are provided for certain populations. In adult and pediatric patients 12 years and older with documented kidney disease, the recommended starting dose is typically reduced to 60 mg once daily. If a dose is missed, the instructions state to take the next dose at the regularly scheduled time, without attempting to double the dose. The duration of use is generally dictated by the persistence of symptomatic need.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allegra Allergy (Fexofenadine)

Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

The primary research for fexofenadine in seasonal allergic rhinitis includes short-term, randomized controlled trials. These controlled study types were used in research exploring how symptoms change over time during periods of heightened symptom activity, such as peak allergy season. The studies applied in trials assessing short-term or episodic symptom patterns, focusing on patient-reported outcomes describing perceived discomfort. Researchers examined endpoints such as symptom intensity or variability related to physical discomfort, including sneezing, a runny nose, and itching of the eyes or throat.

These studies report how symptoms evolved in the observed populations over defined time intervals, typically lasting two to four weeks. Findings describe patterns observed in the studies related to the change in patient-reported symptom scores when fexofenadine was compared to a placebo. Research highlights changes measured during the short-term study period, contributing to the broader evidence landscape for conditions associated with acute or disruptive episodes. It is important to note that study results reflect the specific conditions under which they were conducted.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Research into the use of fexofenadine for chronic idiopathic urticaria—a condition presenting with cycles of stability and flare-ups—also includes randomized, controlled trials. These studies focused on episodes where symptoms become more noticeable. This research explored outcomes related to systemic or functional imbalance, specifically looking at two main measures: the intensity of itching (pruritus) and the size and number of wheals (hives).

In these research scenarios, which often involved intermediate-term follow-up of four to six weeks, studies report how symptoms evolved in the observed populations. Data show patterns related to measured changes in patient-reported scores for these persistent skin manifestations when fexofenadine was studied against a placebo. Evidence derived from settings with varying symptom burdens contributes to understanding symptom patterns in this chronic condition.

What Research Still Seeks to Clarify

A key limitation noted in the research is that follow-up durations were limited, as most key clinical studies were short-term. For both rhinitis and urticaria, long-term effects are not fully established, particularly regarding sustained use over multiple seasons or years. Comparative evidence is lacking in some areas, and evidence quality varies across studies. Research highlights what is known and what is still uncertain, and findings describe group patterns rather than personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Allegra Allergy (FAQ)

Q: Does Allegra Allergy make you feel sleepy or drowsy?

A: Fexofenadine is classified as a non-sedating antihistamine and is less likely to cause drowsiness because it does not readily cross the blood-brain barrier. Regulatory safety documents list drowsiness and fatigue as documented adverse reactions reported by some users.

Q: Is Allegra Allergy considered a non-drowsy antihistamine?

A: Yes, fexofenadine is described in official product information as a non-impairing or non-sedating antihistamine. This classification means it is intended to cause less sedation than older types of antihistamines. Although it is considered non-drowsy, dizziness and drowsiness are still listed among the documented adverse reactions.

Q: Can Allegra Allergy make you feel tired, even if it's non-drowsy?

A: Official safety documents list fatigue, a feeling of being tired, as a commonly reported adverse reaction. This does not preclude the reporting of general tiredness.

Q: What is the difference between Allegra and Allegra D?

A: Allegra Allergy contains only the antihistamine fexofenadine. Combination products, such as Allegra-D, are formulated differently as they contain fexofenadine plus an added ingredient, such as the decongestant pseudoephedrine hydrochloride, which is used to address symptoms such as nasal congestion.

Q: What are the ingredients in Allegra Allergy tablets besides the active one?

A: The active ingredient is fexofenadine. The inactive ingredients, also called excipients, are substances used to form the pill, and generally include ingredients like croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and pregelatinized starch, among other components.

Q: What are the storage guidelines for Allegra Allergy?

A: Official temperature guidelines specify storage between 20 C and 25 C (68 F and 77 F), in a tightly closed container in a cool, dry place. Official guidance recommends keeping it out of the reach of small children.

Q: What happens if a dose of Allegra Allergy is missed?

A: Official administration guidelines advise against attempting to double the dose if one is missed. Instead, the instructions state to take the next scheduled dose at the regular time.

Q: Is Allegra Allergy the same as a decongestant?

A: No, the active ingredient in Allegra Allergy (fexofenadine) is classified as an antihistamine. Its action is to address allergy symptoms by blocking histamine. Products like Allegra-D contain an additional ingredient, such as pseudoephedrine, which acts as a decongestant.

Q: How quickly does Allegra Allergy usually start to work?

A: Official information indicates that the drug starts to exhibit an antihistamine effect within approximately 1 hour after administration. The maximum relief and peak effect are generally observed between 2 and 3 hours post-dose.

Q: How long does the effect of Allegra Allergy last?

A: The antihistamine effect is documented to last for at least 12 hours after administration. This duration supports the typical once- or twice-daily administration.

Q: Can you take Allegra Allergy for skin rashes or hives?

A: Fexofenadine hydrochloride is indicated in regulatory documents for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria, which is the medical term for hives. This is one of the recognized indications in addition to seasonal allergies.

Q: Is Allegra Allergy the same type of medicine as Benadryl?

A: They are both antihistamines, but they belong to different generations. Fexofenadine is a second-generation antihistamine, whereas Benadryl (diphenhydramine) is an older, first-generation antihistamine. The difference is primarily related to the potential for sedation.

Q: Can Allegra Allergy affect alertness or concentration?

A: Fexofenadine is less likely to affect alertness or cognitive function compared to some older antihistamines, because it is designed not to readily cross the blood-brain barrier. However, official guidance advises caution before driving or operating machinery, as individual responses to the medicine can vary.

Q: Is Allegra Allergy available over-the-counter (OTC)?

A: Allegra Allergy (fexofenadine) is generally available for purchase over-the-counter (OTC) in many formulations without requiring a prescription.

Q: Are there different strengths of Allegra Allergy available?

A: The active ingredient fexofenadine is available in different strengths, based on regulatory labeling, which include 30 mg, 60 mg, and 180 mg tablet formulations.

Q: Has Allegra Allergy been studied for use during pregnancy?

A: Official documents advise that use during pregnancy should only occur if the potential benefit is considered to justify the potential risk to the fetus.

Q: Do people report difficulty sleeping with Allegra Allergy?

A: Official regulatory safety data lists insomnia (difficulty sleeping) as a reported adverse reaction.

Q: Are there restrictions on using Allegra Allergy while breastfeeding?

A: Official warnings advise using caution when administering the medicine to nursing mothers. This statement reflects that risks versus benefits should be considered in this population.

Q: Is Allegra Allergy known to cause blurred vision?

A: Blurred vision is listed among the possible documented side effects.

Q: Are there different forms of Allegra Allergy, such as liquid or capsules?

A: Fexofenadine is available in various official forms. These include conventional tablets, capsules, orally disintegrating tablets (ODT), and an oral suspension (liquid) formulation.

Q: Is there a generic version of Allegra Allergy available?

A: Yes, the active ingredient in Allegra Allergy is fexofenadine. Lower-cost generic versions of this medicine, sharing the same active ingredient, are available.

Q: Do studies exist comparing Allegra Allergy to placebo?

A: The primary research used to establish the drug's research findings includes randomized controlled trials where fexofenadine was studied against a placebo (an inactive substance).

Advertisements

How should Allegra Allergy be stored and disposed of?

Storage and Disposal Requirements

Requirement Category Official Regulatory Statement
Labeled storage temperature requirements: Store between 20 and 25 C (68 and 77 F) [Controlled Room Temperature].
Light/moisture protection requirements: Protect from excessive moisture; store in a dry place.
Stability after opening/reconstitution: For orally disintegrating tablets (ODT), use immediately after opening the individual blister.
Child-protection storage requirements: Keep out of the reach of children.
Disposal instructions: Consult a healthcare professional or pharmacist for guidance on proper disposal of unused or expired medicine.

Official labeling mandates that Allegra Allergy must be stored in a tightly closed, original container at controlled room temperature, protected from moisture, and secured away from children. The product integrity must be checked before use; do not use if the seal or packaging is compromised. Disposal of any unused medication should follow the advice of a healthcare professional in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allegra Allergy found in:

A-Z Index: